UPDATE 1-US FDA approves Vera's kidney disease drug

Travere Therapeutics, Inc.
Vera Therapeutics, Inc. Class A
Novan, Inc.

Travere Therapeutics, Inc.

TVTX

0.00

Vera Therapeutics, Inc. Class A

VERA

0.00

Novan, Inc.

NOVN

0.00

Adds details in paragraph 2 and 3

July 7 (Reuters) - The U.S. Food and Drug Administration has approved Vera Therapeutics' VERA.O drug to treat patients with a potentially life-threatening kidney disease, the regulator said on Tuesday, sending its shares up 6.2% in afternoon trading.

The drug Trutakna is a self-administered injectable treatment approved for patients with immunoglobulin A nephropathy, also known as Berger's disease, which causes abnormal protein buildup in the kidneys and could eventually lead to the organ's failure.

Trutakna targets the immune-system proteins BAFF and APRIL, which are involved in the production of disease-causing antibodies in IgA nephropathy and other autoimmune disorders.



This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.